Powered by

New year, new Axovant: CEO Cheruvu on the company's gene therapy pivot

Jan 09, 2019 - FierceBiotech

SAN FRANCISCO—J.P. Morgan week one year ago wasn't Axovant's finest hour. But since Pavan Cheruvu—formerly Roivant's chief people officer—took Axovant's helm in February 2018, the company has been plugging away at becoming a gene therapy player.

“When I joined, at the outset, I had a vision of building a gene therapy company that would be an entirely new company than what Axovant had been before … The small molecule past is now squarely behind us,” said Cheruvu at the J. P. Mor...